129 related articles for article (PubMed ID: 31449916)
1. Characterization of in vitro Mrp2 transporter model based on intestinal organoids.
Zhang L; Liang C; Xu P; Liu M; Xu F; Wang X
Regul Toxicol Pharmacol; 2019 Nov; 108():104449. PubMed ID: 31449916
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
3. Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions.
Chimezie C; Ewing A; Schexnayder C; Bratton M; Glotser E; Skripnikova E; Sá P; Boué S; Stratford RE
J Pharm Sci; 2016 Feb; 105(2):972-981. PubMed ID: 26296158
[TBL] [Abstract][Full Text] [Related]
4. Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes.
Nakanishi T; Shibue Y; Fukuyama Y; Yoshida K; Fukuda H; Shirasaka Y; Tamai I
Drug Metab Dispos; 2011 Jun; 39(6):984-91. PubMed ID: 21415249
[TBL] [Abstract][Full Text] [Related]
5. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter.
Smeets PH; van Aubel RA; Wouterse AC; van den Heuvel JJ; Russel FG
J Am Soc Nephrol; 2004 Nov; 15(11):2828-35. PubMed ID: 15504935
[TBL] [Abstract][Full Text] [Related]
6. 3D organoids derived from the small intestine: An emerging tool for drug transport research.
Zhang Y; Huang S; Zhong W; Chen W; Yao B; Wang X
Acta Pharm Sin B; 2021 Jul; 11(7):1697-1707. PubMed ID: 34386316
[TBL] [Abstract][Full Text] [Related]
7. Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4.
Heredi-Szabo K; Kis E; Molnar E; Gyorfi A; Krajcsi P
J Biomol Screen; 2008 Apr; 13(4):295-301. PubMed ID: 18349419
[TBL] [Abstract][Full Text] [Related]
8. Development of a fluorescence-based assay for drug interactions with human Multidrug Resistance Related Protein (MRP2; ABCC2) in MDCKII-MRP2 membrane vesicles.
Lechner C; Reichel V; Moenning U; Reichel A; Fricker G
Eur J Pharm Biopharm; 2010 Jun; 75(2):284-90. PubMed ID: 20307659
[TBL] [Abstract][Full Text] [Related]
9. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Rhodamine 123 in Three-Dimensional Organoids: A Novel Model for P-Glycoprotein Inhibitor Screening.
Zhang Y; Zeng Z; Zhao J; Li D; Liu M; Wang X
Basic Clin Pharmacol Toxicol; 2016 Oct; 119(4):349-52. PubMed ID: 27060462
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.
Mallants R; Van Oosterwyck K; Van Vaeck L; Mols R; De Clercq E; Augustijns P
Xenobiotica; 2005; 35(10-11):1055-66. PubMed ID: 16393861
[TBL] [Abstract][Full Text] [Related]
12. Transepithelial transport of fluorescent p-glycoprotein and MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted fluid droplets.
Leader JP; O'Donnell MJ
J Exp Biol; 2005 Dec; 208(Pt 23):4363-76. PubMed ID: 16339857
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.
Zamek-Gliszczynski MJ; Xiong H; Patel NJ; Turncliff RZ; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2003 Feb; 304(2):801-9. PubMed ID: 12538836
[TBL] [Abstract][Full Text] [Related]
14. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Liu W; Feng Q; Li Y; Ye L; Hu M; Liu Z
Toxicol Appl Pharmacol; 2012 Dec; 265(3):316-24. PubMed ID: 22982073
[TBL] [Abstract][Full Text] [Related]
15. Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells.
Drennen C; Gorse E; Stratford RE
J Pharm Sci; 2018 Apr; 107(4):1194-1203. PubMed ID: 29247742
[TBL] [Abstract][Full Text] [Related]
16. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
Choi MK; Song IS
J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
[TBL] [Abstract][Full Text] [Related]
17. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
18. MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study.
Holmstock N; Oorts M; Snoeys J; Annaert P
Drug Metab Dispos; 2018 May; 46(5):697-703. PubMed ID: 29523599
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
20. Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport.
Pratt S; Chen V; Perry WI; Starling JJ; Dantzig AH
Eur J Pharm Sci; 2006 Apr; 27(5):524-32. PubMed ID: 16337112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
